Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.11 (
CD10
)
9,792
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A new human pre-B acute lymphoblastic leukemia cell line (KMO-90) was established from the bone marrow sample of a 12-year-old girl with acute lymphoblastic leukemia (ALL) carrying 1;19 chromosome translocation. KMO-90 cells expressed HLA-DR,
CD10
, CD19, and CD22 antigens. These cells had also cytoplasmic immunoglobulin lacking surface immunoglobulin, indicating that these had a pre-B phenotype. Chromosome analysis of this cell line showed 48, XX, +8, +19, t(1;19)(q23;p13). Southern blot analysis showed the same sized rearrangements of the E2A gene in KMO-90 cells as those in the original leukemic cells. By means of reverse transcriptase-polymerase chain reaction analysis, we detected E2A/PBX1 fusion transcripts in KMO-90 cells. KMO-90 is useful when studying the role of the 1;19 translocation in the etiology of pre-B ALL. Furthermore, we studied alterations of the p53 gene in this cell line by polymerase chain reaction, single-strand conformation polymorphism analysis. KMO-90 cells were identified to have a point mutation at codon 177 (CCC-->
TCC
) of the p53 gene, suggesting that alterations of the p53 gene may have an important role in the establishment of this cell line.
...
PMID:Establishment of a new human pre-B acute lymphoblastic leukemia cell line (KMO-90) with 1;19 translocation carrying p53 gene alterations. 841 23
CD10
is a cell surface zinc metalloprotease expressed in a variety of normal cell types, including lymphoid precursor cells, germinal centre B lymphocytes and some epithelial cells. The aim of this study was to assess the prognostic value of
CD10
in bladder carcinoma. The expression of
CD10
was immunohistochemically assessed in 49 cases of primary bladder carcinoma in comparison with 10 non-neoplastic normal bladder mucosa specimens. 27 cases (55%) were tumour
CD10
(+) and tumour
CD10
positivity was significantly correlated with advanced stage, larger tumor size, and shorter mean survival time. Extensive tumoral staining assessed by H score further documented the positive correlation of
CD10
with worse prognostic factors in the whole group and its subdivisions (SCC and
TCC
), in addition to its significant association with bilharziasis in SCC. Only
CD10
-tumour positivity in the whole group proved to be an independent prognostic factor for overall survival by multivariate analysis. No significant value of stromal
CD10
expression in the investigated bladder carcinoma cases was found. This study points to the prognostic value of neoplastic
CD10
expression in bladder carcinoma and its possible importance in facilitating tumour invasion and metastasis. Bilharziasis could have a role in upregulation of
CD10
expression in SCC.
...
PMID:CD10 expression in tumour and stromal cells of bladder carcinoma: an association with bilharziasis. 1809 52
Identification of prognostic markers in bladder carcinoma comprises a major clinical issue and therapeutic target.
CD10
and the adhesion molecule E-cadherin (E-cad) are expressed in a variety of normal tissues and their neoplasms.
CD10
is able to degrade extracellular matrix and other proteins, including adhesion molecules. The roles of
CD10
and E-cad and their relationship in the development and progression of bladder carcinoma are poorly understood. The aim of this study was to investigate the expression of
CD10
and E-cad in bladder carcinomas and relate the results to the established prognostic factors. This study included 144 patients with bladder carcinoma, including 72 with transitional cell carcinoma (
TCC
; 30 bilharzial and 42 nonbilharzial) and 72 with squamous cell carcinoma (SCC; 38 bilharzial and 34 nonbilharzial). Immunohistochemical analysis for both
CD10
and E-cad were carried out on paraffin-fixed sections of neoplastic bladder tissues.
CD10
tumor cells,
CD10
stromal cells, and E-cad were expressed in 56%, 58%, and 51% of cancer bladder cases, respectively. There was a statistically significant correlation between percentage of tumor cells positively stained by
CD10
and each of the tumor grade, clinical stage, and lymph node metastasis of both
TCC
and SCC. There was a significant statistical correlation between immunostaining by E-cad marker and each of the tumor grade, clinical stage, and lymph node metastasis of
TCC
, but no such association with SCC. The frequency of stromal expression of
CD10
was higher in bilharzial-associated bladder carcinomas than in nonbilharzial ones, and these results were statistically significant. In conclusion, increased expression of
CD10
in the tumor and stromal cells of both
TCC
and SCC and decreased expression of E-cad in the tumor cells of only
TCC
are strongly correlated with tumor progression, invasion, and metastasis in human bladder cancer.
...
PMID:CD10 and E-cad expression in urinary bladder urothelial and squamous cell carcinoma. 2333 95